THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS

被引：361
|
作者：
EICHELBAUM, M
GROSS, AS
机构：
[1] Dr Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, D-7000 Stuttgart 50
来源：
PHARMACOLOGY & THERAPEUTICS | 1990年 / 46卷 / 03期
关键词：
D O I：
10.1016/0163-7258(90)90025-W
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
It has been established that the metabolism of more than twenty drugs, including antiarrhythmics, β-adrenoceptor antagonists, antidepressants, opiates and neuroleptics is catalyzed by cytochrome P-450dbl. The activity of this P-450 isozyme is under genetic rather than environmental control. This article discusses the therapeutic implications for each of the classes of drugs affected by this genetic polymorphism in drug metabolism. Not only are the problems associated with poor metabolizers who are unable to metabolize the compounds discussed, but it is also emphasized that it is difficult to attain therapeutic plasma concentrations for some drugs in high activity extensive metabolizers. © 1990.
引用
收藏
页码：377 / 394
页数：18
相关论文
共 50 条
  • [11] DEFICIENT METABOLISM OF DEBRISOQUINE AND SPARTEINE
    INABA, T
    OTTON, SV
    KALOW, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (04) : 547 - 549
  • [12] CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM
    BROSEN, K
    GRAM, LF
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) : 537 - 547
  • [13] CLINICAL IMPLICATIONS OF GENETIC-POLYMORPHISM IN DRUG-METABOLISM
    TUCKER, GT
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1994, 46 : 417 - 424
  • [14] GENETIC-POLYMORPHISM OF PROPAFENONE METABOLISM
    TRENK, D
    WAGNER, F
    JAHNCHEN, E
    EICHELBAUM, E
    ZEKORN, C
    HARNASCH, P
    HAUF, G
    ROSKAMM, H
    ZEITSCHRIFT FUR KARDIOLOGIE, 1987, 76 : 81 - 81
  • [15] DEBRISOQUINE-TYPE GENETIC-POLYMORPHISM DIFFERENCES IN MEDIFOXAMINE PHARMACOKINETICS
    SALEH, S
    CAULFIELD, M
    LLEDO, P
    JOHNSTON, A
    TURNER, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (06) : 2387 - 2387
  • [16] THE METABOLISM OF MEXILETINE IN RELATION TO THE DEBRISOQUINE SPARTEINE-TYPE POLYMORPHISM OF DRUG OXIDATION
    BROLY, F
    VANDAMME, N
    LIBERSA, C
    LHERMITTE, M
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (04) : 459 - 466
  • [17] GENETIC-POLYMORPHISM OF DRUG-METABOLISM
    DUMONT, E
    BELPAIRE, F
    ACTA CLINICA BELGICA, 1989, 44 (03): : 157 - 160
  • [18] THEOPHYLLINE METABOLISM IN RELATION TO ANTIPYRINE, DEBRISOQUINE, AND SPARTEINE METABOLISM
    DAHLQVIST, R
    BERTILSSON, L
    BIRKETT, DJ
    EICHELBAUM, M
    SAWE, J
    SJOQVIST, F
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (06) : 815 - 821
  • [19] MODERN CONCEPTS ON METABOLISM AND GENETIC-POLYMORPHISM OF COLLAGEN
    WLADIMIRTSEV, WA
    LEBEDEV, DA
    VOPROSY MEDITSINSKOI KHIMII, 1979, 25 (06): : 659 - 672
  • [20] GENETIC-POLYMORPHISM OF HEPATIC DRUG-METABOLISM
    LARREY, D
    PESSAYRE, D
    BENHAMOU, JP
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1985, 9 (6-7): : 522 - 531
12345